UTHR
United Therapeutics Corporation
Price Chart
Latest Quote
$535.67
+6.62 (+1.25%)
Current Price
| Previous Close | $529.05 |
| Open | $529.29 |
| Day High | $543.56 |
| Day Low | $528.65 |
| Volume | 416,701 |
Stock Information
| Shares Outstanding | 42.45M |
| Cash Equivalents | $2.15B |
| Revenue | $3.17B |
| Net Income | $1.29B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $22.74B |
| P/E Ratio | 19.80 |
| EPS (TTM) | $27.05 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $20.58B |
| Sales | $3.17B |
| Income | $1.29B |
| Book/sh | $139.98 |
| Cash/sh | $50.74 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 4.12 |
| Current Ratio | 4.79 |
| EPS Growth TTM | -14.70% |
Returns & Margins
| ROA | 12.62% |
| ROE | 20.26% |
| Gross Margin | 86.58% |
| Operating Margin | 41.69% |
| Profit Margin | 40.62% |
Ownership
| Insider Ownership | 2.05% |
| Institutional Ownership | 101.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 16.21 |
| PEG | 2.22 |
| P/S | 7.17 |
| P/B | 3.83 |
Analyst Data
| Recommendation | buy |
| Target Price | $663.46 |
Technical Indicators
| SMA20 | $543.43 |
| SMA50 | $553.79 |
| SMA200 | $510.23 |
| RSI | 46.36 |
| ATR | 13.4407 |
| Shares Float | 38.91M |
| Short Float | 5.84% |
| Short Ratio | 3.62 |
| Volatility | 0.58 |
| Rel Volume | 0.77 |
Performance History
| Week | -2.08% |
| Month | -2.30% |
| Quarter | -7.72% |
| 6 Months | +12.60% |
| YTD | +7.84% |
| Year | +79.66% |
| 3 Years | +132.99% |
| 5 Years | +185.46% |
| 10 Years | +383.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $535.67 | 422,200 |
| 2026-07-16 | $529.05 | 350,900 |
| 2026-07-15 | $531.79 | 448,100 |
| 2026-07-14 | $526.66 | 372,600 |
| 2026-07-13 | $535.57 | 303,800 |
| 2026-07-10 | $547.06 | 307,800 |
| 2026-07-09 | $552.48 | 302,800 |
| 2026-07-08 | $554.34 | 299,400 |
| 2026-07-07 | $563.70 | 513,700 |
| 2026-07-06 | $547.25 | 326,600 |
| 2026-07-02 | $555.91 | 534,400 |
| 2026-07-01 | $547.15 | 422,600 |
| 2026-06-30 | $541.83 | 551,100 |
| 2026-06-29 | $544.92 | 420,300 |
| 2026-06-26 | $542.66 | 1,022,200 |
| 2026-06-25 | $543.39 | 276,500 |
| 2026-06-24 | $549.90 | 377,600 |
| 2026-06-23 | $544.33 | 1,081,300 |
| 2026-06-22 | $538.30 | 620,900 |
| 2026-06-18 | $536.59 | 2,002,000 |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
đ° Latest News
Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
Simply Wall St. âĸ 2026-07-15T01:13:34Z
United Therapeutics (UTHR) Stock Looks Cheap On Fair Value Despite Strong Returns
Simply Wall St. âĸ 2026-07-12T12:07:56Z
BETA Technologies (BETA), Multistate Collaborative Complete Inaugural eVTOL Integration Pilot Program Flights
Insider Monkey âĸ 2026-07-12T07:59:21Z
United Therapeutics (UTHR) Following FDA Approval Is The Stock Fully Valued
Simply Wall St. âĸ 2026-07-11T19:08:30Z
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
Zacks âĸ 2026-07-09T18:26:00Z
Is United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation?
Insider Monkey âĸ 2026-07-08T14:50:14Z
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
Zacks âĸ 2026-07-03T12:55:00Z
BridgeBio gets funding for drug launch; United buys into cell therapy
BioPharma Dive âĸ 2026-07-01T11:29:00Z
Is MannKind Corporation (MNKD) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-29T19:35:11Z
Bull of the Day: Neurocrine Biosciences (NBIX)
Zacks âĸ 2026-06-29T08:00:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $384,400,000 | $309,700,000 | $257,500,000 | $151,600,000 |
| Cost Of Revenue | $384,400,000 | $309,700,000 | $257,500,000 | $151,600,000 |
| Total Revenue | $3,182,700,000 | $2,877,400,000 | $2,327,500,000 | $1,936,300,000 |
| Operating Revenue | $3,182,700,000 | $2,877,400,000 | $2,327,500,000 | $1,936,300,000 |
| Expenses | ||||
| Interest Expense | $19,500,000 | $42,900,000 | $59,300,000 | $32,400,000 |
| Total Expenses | $1,665,500,000 | $1,429,300,000 | $1,142,600,000 | $956,600,000 |
| Other Income Expense | $24,200,000 | $-65,300,000 | $-14,000,000 | $-41,900,000 |
| Other Non Operating Income Expenses | $48,900,000 | $5,800,000 | $-14,000,000 | $-40,200,000 |
| Net Non Operating Interest Income Expense | $172,500,000 | $156,200,000 | $103,400,000 | $12,800,000 |
| Interest Expense Non Operating | $19,500,000 | $42,900,000 | $59,300,000 | $32,400,000 |
| Operating Expense | $1,281,100,000 | $1,119,600,000 | $885,100,000 | $805,000,000 |
| Selling And Marketing Expense | $118,600,000 | $96,300,000 | $81,800,000 | $70,800,000 |
| General And Administrative Expense | $612,500,000 | $542,300,000 | $395,300,000 | $411,300,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Net Interest Income | $172,500,000 | $156,200,000 | $103,400,000 | $12,800,000 |
| Interest Income | $192,000,000 | $199,100,000 | $162,700,000 | $45,200,000 |
| Normalized Income | $1,353,941,300 | $1,250,312,222 | $984,800,000 | $728,609,000 |
| Net Income From Continuing And Discontinued Operation | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Total Operating Income As Reported | $1,492,500,000 | $1,377,000,000 | $1,184,900,000 | $979,700,000 |
| Net Income Common Stockholders | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Net Income | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Net Income Including Noncontrolling Interests | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Net Income Continuous Operations | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Pretax Income | $1,713,900,000 | $1,539,000,000 | $1,274,300,000 | $950,600,000 |
| Special Income Charges | $-24,700,000 | $-71,100,000 | $0 | $-1,700,000 |
| Interest Income Non Operating | $192,000,000 | $199,100,000 | $162,700,000 | $45,200,000 |
| Operating Income | $1,517,200,000 | $1,448,100,000 | $1,184,900,000 | $979,700,000 |
| Gross Profit | $2,798,300,000 | $2,567,700,000 | $2,070,000,000 | $1,784,700,000 |
| Per Share | ||||
| Diluted EPS | $27.86 | $24.64 | $19.81 | $15.00 |
| Basic EPS | $30.13 | $26.44 | $21.04 | $15.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $-5,458,700 | $-15,887,778 | $0 | $-391,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,843,700,000 | $1,725,500,000 | $1,386,800,000 | $1,036,000,000 |
| Total Unusual Items | $-24,700,000 | $-71,100,000 | $0 | $-1,700,000 |
| Total Unusual Items Excluding Goodwill | $-24,700,000 | $-71,100,000 | $0 | $-1,700,000 |
| Reconciled Depreciation | $85,600,000 | $72,500,000 | $53,200,000 | $51,300,000 |
| EBITDA (Bullshit earnings) | $1,819,000,000 | $1,654,400,000 | $1,386,800,000 | $1,034,300,000 |
| EBIT | $1,733,400,000 | $1,581,900,000 | $1,333,600,000 | $983,000,000 |
| Diluted Average Shares | $47,900,000 | $48,500,000 | $49,700,000 | $48,500,000 |
| Basic Average Shares | $44,300,000 | $45,200,000 | $46,800,000 | $45,500,000 |
| Diluted NI Availto Com Stockholders | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Tax Provision | $379,200,000 | $343,900,000 | $289,500,000 | $223,300,000 |
| Other Special Charges | $3,000,000 | $71,100,000 | - | - |
| Impairment Of Capital Assets | $21,700,000 | $0 | $0 | - |
| Research And Development | $550,000,000 | $481,000,000 | $408,000,000 | $322,900,000 |
| Selling General And Administration | $731,100,000 | $638,600,000 | $477,100,000 | $482,100,000 |
| Other Gand A | $501,000,000 | $432,800,000 | $374,200,000 | $333,200,000 |
| Salaries And Wages | $111,500,000 | $109,500,000 | $21,100,000 | $78,100,000 |
| Write Off | - | $0 | $0 | $1,700,000 |
Fetched: 2026-07-08
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,979,700,000 | $6,332,100,000 | $5,870,600,000 | $4,752,200,000 |
| Total Assets | $7,880,000,000 | $7,364,000,000 | $7,167,000,000 | $6,044,500,000 |
| Total Non Current Assets | $4,177,500,000 | $3,490,100,000 | $3,616,000,000 | $2,664,200,000 |
| Other Non Current Assets | $196,900,000 | $222,100,000 | $151,800,000 | $114,300,000 |
| Non Current Deferred Assets | $357,700,000 | $458,400,000 | $394,800,000 | $327,700,000 |
| Non Current Deferred Taxes Assets | $357,700,000 | $458,400,000 | $394,800,000 | $327,700,000 |
| Investmentin Financial Assets | $1,776,700,000 | $1,475,300,000 | $1,909,800,000 | - |
| Goodwill And Other Intangible Assets | $116,500,000 | $111,900,000 | $114,200,000 | $44,500,000 |
| Other Intangible Assets | $84,200,000 | $79,600,000 | $80,500,000 | $16,500,000 |
| Current Assets | $3,702,500,000 | $3,873,900,000 | $3,551,000,000 | $3,380,300,000 |
| Other Current Assets | $248,900,000 | $169,700,000 | $166,200,000 | $219,200,000 |
| Inventory | $183,100,000 | $157,900,000 | $111,800,000 | $102,000,000 |
| Receivables | $350,200,000 | $279,300,000 | $278,900,000 | $220,400,000 |
| Accounts Receivable | $350,200,000 | $279,300,000 | $278,900,000 | $220,400,000 |
| Cash And Cash Equivalents | $1,557,100,000 | $1,697,200,000 | $1,207,700,000 | $961,200,000 |
| Debt | ||||
| Total Debt | - | $300,000,000 | $700,000,000 | $800,000,000 |
| Current Debt And Capital Lease Obligation | - | $300,000,000 | $400,000,000 | - |
| Current Debt | - | $300,000,000 | $400,000,000 | - |
| Other Current Borrowings | - | $300,000,000 | $400,000,000 | - |
| Long Term Debt And Capital Lease Obligation | - | - | $300,000,000 | $800,000,000 |
| Long Term Debt | - | - | $300,000,000 | $800,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $783,800,000 | $920,000,000 | $1,182,200,000 | $1,247,800,000 |
| Total Non Current Liabilities Net Minority Interest | $223,200,000 | $181,900,000 | $377,800,000 | $904,600,000 |
| Other Non Current Liabilities | $223,200,000 | $181,900,000 | $77,800,000 | $104,600,000 |
| Current Liabilities | $560,600,000 | $738,100,000 | $804,400,000 | $343,200,000 |
| Other Current Liabilities | $72,600,000 | $82,600,000 | $71,000,000 | $32,500,000 |
| Payables And Accrued Expenses | $488,000,000 | $344,500,000 | $298,000,000 | $229,900,000 |
| Payables | $7,100,000 | $6,000,000 | $5,600,000 | $4,100,000 |
| Accounts Payable | $7,100,000 | $6,000,000 | $5,600,000 | $4,100,000 |
| Equity | ||||
| Common Stock Equity | $7,096,200,000 | $6,444,000,000 | $5,984,800,000 | $4,796,700,000 |
| Total Equity Gross Minority Interest | $7,096,200,000 | $6,444,000,000 | $5,984,800,000 | $4,796,700,000 |
| Stockholders Equity | $7,096,200,000 | $6,444,000,000 | $5,984,800,000 | $4,796,700,000 |
| Gains Losses Not Affecting Retained Earnings | $900,000 | $-3,400,000 | $-12,800,000 | $-55,500,000 |
| Other Equity Adjustments | $900,000 | $-3,400,000 | $-12,800,000 | $-55,500,000 |
| Retained Earnings | $8,556,900,000 | $7,222,200,000 | $6,027,100,000 | $5,042,300,000 |
| Other | ||||
| Treasury Shares Number | $32,809,088 | $30,166,590 | $26,619,216 | $26,619,216 |
| Ordinary Shares Number | $43,643,165 | $44,831,306 | $47,040,545 | $46,032,064 |
| Share Issued | $76,452,253 | $74,997,896 | $73,659,761 | $72,651,280 |
| Tangible Book Value | $6,979,700,000 | $6,332,100,000 | $5,870,600,000 | $4,752,200,000 |
| Invested Capital | $7,096,200,000 | $6,744,000,000 | $6,684,800,000 | $5,596,700,000 |
| Working Capital | $3,141,900,000 | $3,135,800,000 | $2,746,600,000 | $3,037,100,000 |
| Total Capitalization | $7,096,200,000 | $6,444,000,000 | $6,284,800,000 | $5,596,700,000 |
| Treasury Stock | $4,260,400,000 | $3,474,500,000 | $2,579,200,000 | $2,579,200,000 |
| Additional Paid In Capital | $2,798,000,000 | $2,698,900,000 | $2,549,000,000 | $2,388,400,000 |
| Capital Stock | $800,000 | $800,000 | $700,000 | $700,000 |
| Common Stock | $800,000 | $800,000 | $700,000 | $700,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $0 | $11,000,000 | $35,400,000 | $80,800,000 |
| Current Accrued Expenses | $480,900,000 | $338,500,000 | $292,400,000 | $225,800,000 |
| Investments And Advances | $1,776,700,000 | $1,475,300,000 | $1,909,800,000 | $1,316,200,000 |
| Available For Sale Securities | $1,776,700,000 | $1,475,300,000 | $1,909,800,000 | - |
| Goodwill | $32,300,000 | $32,300,000 | $33,700,000 | $28,000,000 |
| Net PPE | $1,729,700,000 | $1,222,400,000 | $1,045,400,000 | $861,500,000 |
| Accumulated Depreciation | $-567,800,000 | $-491,200,000 | $-428,200,000 | $-382,700,000 |
| Gross PPE | $2,297,500,000 | $1,713,600,000 | $1,473,600,000 | $1,244,200,000 |
| Construction In Progress | $592,700,000 | $218,200,000 | $259,100,000 | $110,900,000 |
| Machinery Furniture Equipment | $493,600,000 | $449,700,000 | $381,200,000 | $353,900,000 |
| Buildings And Improvements | $944,700,000 | $863,800,000 | $685,300,000 | $636,700,000 |
| Land And Improvements | $266,500,000 | $181,900,000 | $148,000,000 | $142,700,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $117,200,000 | $95,000,000 | $55,700,000 | $50,700,000 |
| Work In Process | $35,300,000 | $34,300,000 | $34,400,000 | $33,300,000 |
| Raw Materials | $30,600,000 | $28,600,000 | $21,700,000 | $18,000,000 |
| Other Short Term Investments | $1,363,200,000 | $1,569,800,000 | $1,786,400,000 | $1,877,500,000 |
Fetched: 2026-07-08
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,035,200,000 | $1,080,600,000 | $747,600,000 | $663,700,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,561,200,000 | $1,327,100,000 | $978,000,000 | $802,500,000 |
| Cash Flow From Continuing Operating Activities | $1,561,200,000 | $1,327,100,000 | $978,000,000 | $802,500,000 |
| Operating Gains Losses | - | - | - | $-7,100,000 |
| Investing Activities | ||||
| Capital Expenditure | $-526,000,000 | $-246,500,000 | $-230,400,000 | $-138,800,000 |
| Investing Cash Flow | $-551,300,000 | $417,200,000 | $-719,600,000 | $-811,500,000 |
| Cash Flow From Continuing Investing Activities | $-551,300,000 | $417,200,000 | $-719,600,000 | $-811,500,000 |
| Net Other Investing Changes | $-10,400,000 | $-28,500,000 | $-23,000,000 | $3,500,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,016,600,000 | $-1,012,200,000 | $-13,800,000 | $-11,400,000 |
| Financing Cash Flow | $-1,150,000,000 | $-1,254,800,000 | $-11,900,000 | $75,400,000 |
| Cash Flow From Continuing Financing Activities | $-1,150,000,000 | $-1,254,800,000 | $-11,900,000 | $75,400,000 |
| Net Other Financing Charges | $-16,500,000 | $-2,700,000 | $-2,700,000 | $-7,500,000 |
| Net Common Stock Issuance | $-1,016,600,000 | $-1,012,200,000 | $-13,800,000 | $-11,400,000 |
| Other | ||||
| Repayment Of Debt | $-500,000,000 | $-400,000,000 | $-100,000,000 | $-800,000,000 |
| Issuance Of Debt | $200,000,000 | $0 | $0 | $800,000,000 |
| Interest Paid Supplemental Data | $13,500,000 | $40,200,000 | $56,000,000 | $29,100,000 |
| End Cash Position | $1,557,100,000 | $1,697,200,000 | $1,207,700,000 | $961,200,000 |
| Beginning Cash Position | $1,697,200,000 | $1,207,700,000 | $961,200,000 | $894,800,000 |
| Changes In Cash | $-140,100,000 | $489,500,000 | $246,500,000 | $66,400,000 |
| Proceeds From Stock Option Exercised | $183,100,000 | $160,100,000 | $104,600,000 | $94,300,000 |
| Common Stock Payments | $-1,016,600,000 | $-1,012,200,000 | $-13,800,000 | $-11,400,000 |
| Net Issuance Payments Of Debt | $-300,000,000 | $-400,000,000 | $-100,000,000 | $0 |
| Net Short Term Debt Issuance | $-300,000,000 | $-400,000,000 | $-100,000,000 | $0 |
| Short Term Debt Payments | $-500,000,000 | $-400,000,000 | $-100,000,000 | $-800,000,000 |
| Short Term Debt Issuance | $200,000,000 | $0 | $0 | $800,000,000 |
| Net Investment Purchase And Sale | $40,100,000 | $722,700,000 | $-377,000,000 | $-674,700,000 |
| Sale Of Investment | $3,445,500,000 | $2,368,800,000 | $2,137,300,000 | $1,033,900,000 |
| Purchase Of Investment | $-3,405,400,000 | $-1,646,100,000 | $-2,514,300,000 | $-1,708,600,000 |
| Net Business Purchase And Sale | $-55,000,000 | $-30,500,000 | $-89,200,000 | $-1,500,000 |
| Purchase Of Business | $-55,000,000 | $-30,500,000 | $-89,200,000 | $-1,500,000 |
| Net Intangibles Purchase And Sale | $-5,500,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-5,500,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-520,500,000 | $-246,500,000 | $-230,400,000 | $-138,800,000 |
| Purchase Of PPE | $-520,500,000 | $-246,500,000 | $-230,400,000 | $-138,800,000 |
| Change In Working Capital | $-106,500,000 | $3,900,000 | $-33,400,000 | $-141,200,000 |
| Change In Other Working Capital | $-80,900,000 | $8,500,000 | $-18,400,000 | $-150,600,000 |
| Change In Payables And Accrued Expense | $97,900,000 | $42,700,000 | $57,100,000 | $44,500,000 |
| Change In Inventory | $-52,600,000 | $-46,900,000 | $-13,600,000 | $-13,400,000 |
| Change In Receivables | $-70,900,000 | $-400,000 | $-58,500,000 | $-21,700,000 |
| Changes In Account Receivables | $-70,900,000 | $-400,000 | $-58,500,000 | $-21,700,000 |
| Other Non Cash Items | $-19,700,000 | $-24,300,000 | $-4,900,000 | $52,500,000 |
| Stock Based Compensation | $147,700,000 | $144,000,000 | $39,100,000 | $106,800,000 |
| Asset Impairment Charge | $21,700,000 | $0 | $3,600,000 | $12,900,000 |
| Deferred Tax | $97,700,000 | $-64,100,000 | $-64,400,000 | - |
| Deferred Income Tax | $97,700,000 | $-64,100,000 | $-64,400,000 | - |
| Depreciation Amortization Depletion | $85,600,000 | $72,500,000 | $53,200,000 | $51,300,000 |
| Depreciation And Amortization | $85,600,000 | $72,500,000 | $53,200,000 | $51,300,000 |
| Amortization Cash Flow | $900,000 | $900,000 | $300,000 | $100,000 |
| Amortization Of Intangibles | $900,000 | $900,000 | $300,000 | $100,000 |
| Depreciation | $84,700,000 | $71,600,000 | $52,900,000 | $51,200,000 |
| Net Income From Continuing Operations | $1,334,700,000 | $1,195,100,000 | $984,800,000 | $727,300,000 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $-800,000,000 |
| Long Term Debt Issuance | - | - | - | $800,000,000 |
| Sale Of Business | - | - | - | $8,600,000 |
| Sale Of PPE | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $-7,100,000 |
Fetched: 2026-07-08